Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology

Volumn 66, Issue 3, 2012, Pages 369-375

  Robinson, Amanda ^a,d   Kardos, Marisa ^a,b,d   Kimball, Alexandra B ^a,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CURTIS   (United States)

Author keywords

Physician Global Assessment; Psoriasis Area and Severity Index; psoriasis severity assessment tools

Indexed keywords

ADALIMUMAB; ALEFACEPT; BRIAKINUMAB; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

BODY SURFACE; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; PHOTOTHERAPY; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; REVIEW; SYSTEMATIC REVIEW;

EID: 84857448226     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.01.022     Document Type: Article

References (41)

1. P.I. Spuls, L.L. Lecluse, M.L. Poulsen, J.D. Bos, R.S. Stern, and T. Nijsten How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review J Invest Dermatol 130 2010 933 943
2. E. Puzenat, V. Bronsard, S. Prey, P.A. Gourraud, S. Aractingi, and M. Bagot What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature J Eur Acad Dermatol Venereol 24 Suppl 2010 10 16
3. Department of Health and Human Services. Public Health Service. Food and Drug Administration. Dermatologic and Ophthalmic Drugs Advisory Committee 49th Meeting. March 20, 1998.
4. T. Nijsten, C.W.N. Looman, and R.S. Stern Clinical severity of psoriasis in the last 20 years of PUVA study Arch Dermatol 143 2007 1113 1121 (Pubitemid 47443362)
5. V.M.R. Heydendael, P.I. Spuls, B.C. Opmeer, C.A.J.M. de Borgie, J.B. Reitsma, and W.F.M. Goldschmidt Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665 (Pubitemid 36975998)
6. J. Berth-Jones, K. Grotzinger, C. Rainville, B. Pham, J. Huang, and S. Daly A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment Br J Dermatol 155 2006 707 713 (Pubitemid 44352550)
7. J.P. Ortonne Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients J Eur Acad Dermatol Venereol 17 Suppl 2003 12 16
8. C.L. Leonardi, J.L. Powers, R.T. Matheson Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022 (Pubitemid 37448924)
9. G.G. Kreuger, K.A. Papp, D.B. Stough, K.H. Loven, W.P. Gulliver, and C.N. Ellis A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis J Am Acad Dermatol 47 2002 821 833 (Pubitemid 35403039)
10. M. Lebwohl, S.K. Tyring, T.K. Hamilton, D. Toth, S. Glazer, and N.H. Tawfik A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2003 2004 2013 (Pubitemid 37448923)
11. K.A. Papp, R. Bressinck, S. Fretzin, B. Goffe, S. Kempers, and K. Gordon Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial Int J Dermatol 45 2006 605 614
12. C.H. Gribetz, R. Blum, C. Brady, S. Cohen, and M. Lebwohl An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis J Am Acad Dermatol 53 2005 73 75 (Pubitemid 40826697)
13. G.G. Krueger, and C.N. Ellis Alefacept therapy produces remission for patients with chronic plaque psoriasis Br J Dermatol 148 2003 784 788
14. K.B. Gordon, and R.G. Langley Remittive effects of intramuscular alefacept in psoriasis J Drugs Dermatol 2 2003 624 628
15. A. Menter, K. Gordon, W. Carey, T. Hamilton, S. Glazer, and I. Caro Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis Arch Dermatol 141 2005 31 38 (Pubitemid 40144437)
16. K.B. Gordon, K.A. Papp, and T.K. Hamilton Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial JAMA 290 2003 3073 3080 (Pubitemid 37548113)
17. M. Lebwohl, E. Christophers, R. Langley, J.P. Ortonne, J. Roberts, C.E.M. Griffiths Alefacept Clinical Study Group An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 2003 719 727 (Pubitemid 36705938)
18. L. Dubertret, W. Sterry, J.D. Bos, S. Chimenti, S. Shumack, and C.G. Larsen Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial Br J Dermatol 155 2006 170 181 (Pubitemid 43876411)
19. A.B. Gottlieb, R.T. Matheson, N. Lowe, G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632 (Pubitemid 37523083)
20. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E.M. Griffiths, and A.M. Nakansishi A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312 (Pubitemid 40933433)
21. J.H. Saurat, G. Stingl, and L. Dubertret Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 606
22. B. Elewski, C. Leonardi, A.B. Gottlieb, B.E. Strober, M.A. Simiens, and M. Dunn Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis Br J Dermatol 156 2007 138 142 (Pubitemid 44924157)
23. P.C.M. Van de Kerkhof, S. Segaert, M. Lahfa, T.A. Luger, Z. Karolyi, and A. Kaszuba Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension Br J Dermatol 159 2008 1177 1185
24. C.L. Leonardi, K.A. Papp, K.B. Gordon, A. Menter, S.R. Feldman, and I. Caro Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial J Am Acad Dermatol 52 2005 425 433
25. K.B. Gordon, R.G. Langley, and C. Leonardi Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study J Am Acad Dermatol 55 2006 598 606 (Pubitemid 44436647)
26. I. Landells, A.S. Paller, D. Pariser, G. Kricorian, J. Foehl, and C. Molta Efficacy and safety of etanercept in children and adolescents aged ≥ 8 years with severe plaque psoriasis Eur J Dermatol 20 2010 323 328
27. A.S. Paller, E.C. Siegfried, R.G. Langley, A.B. Gottlieb, D. Pariser, and I. Landells Etanercept treatment for children and adolescents with plaque psoriasis N Engl J Med 358 2008 241 251
28. A. Asahina, H. Nakagawa, T. Etoh, and M. Ohtsuki Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a phase II/III randomized controlled study J Dermatol 37 2010 299 310
29. C. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, and Y. Wang Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
30. K.A. Papp, R.G. Langley, M. Lebwohl, G. Kreuger, P. Szapary, and N. Yeilding Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684 (Pubitemid 351671884)
31. C.E.M. Griffiths, B.E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, and N. Yeilding Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
32. A. Menter, S.K. Tyring, and K. Gordon Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115 (Pubitemid 350298146)
33. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 2007 31e1-15
34. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542 (Pubitemid 39278071)
35. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, and C. Guzzo Infliximab induction and maintenance therapy for moderate to severe psoriasis: a phase III multicenter, double-blind trial Lancet 366 2005 1367 1374 (Pubitemid 41443403)
36. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial Lancet 357 2001 1842 1847 (Pubitemid 32539117)
37. M. Papoutsaki, M.S. Chimenti, A. Costanzo, M. Talamonti, A. Zangrilli, and A. Giunta Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics J Am Acad Dermatol 57 2007 269 275 (Pubitemid 47048857)
38. M.B. Alora-Palli, A.C. Perkins, A. Van Cott, and A.B. Kimball Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream Am J Clin Dermatol 11 2010 275 283
39. A.B. Gottlieb, U. Chaudari, D.G. Baker, M. Perate, and L.T. Dooley The National Psoriasis Foundation Psoriasis Score system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison J Drugs Dermatol 2 2003 260 266
40. R.S. Stern Poor metrics and lost opportunity J Am Acad Dermatol 63 2010 718 719
41. C.C. Jacobson, and A.B. Kimball Rethinking the psoriasis area and severity index: the impact of area should be decreased Br J Dermatol 151 2004 381 387 (Pubitemid 39215151)